{"id":"W2242926421","doi":"10.1200/jco.2007.25.18_suppl.14560","title":"Capecitabine (X) compared to X + erlotinib (E) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Interim efficacy results from a randomized phase II study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Nausea; Adverse effect; Oxaliplatin; Colorectal cancer; Gastroenterology; Clinical endpoint; Discontinuation; Interim analysis; Oncology; Randomized controlled trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001876169,0.001178288,0.001966235,0.0003620433,0.0002471952,0.0007690665,0.0006435399,0.0008830766,0.003538197],"category_scores_gemma":[0.001230858,0.000563962,0.001674394,0.0003336873,0.0006746488,0.0005854933,0.0003076589,0.001732052,0.000511794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000525353,"about_ca_system_score_gemma":0.0007354579,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007586903,"about_ca_topic_score_gemma":0.001454288,"domain_scores_codex":[0.9994894,0.0003287234,0.00003641752,0.00005389902,0.00003121022,0.0000602107],"domain_scores_gemma":[0.9991249,0.000276436,0.0002113054,0.00005106549,0.0000350595,0.0003011993],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9724584,0.007647974,0.0008873534,0.0003110736,0.0005114486,0.00003547183,0.00003802279,0.0002786587,0.003262849,0.00003847517,0.0003967022,0.01413365],"study_design_scores_gemma":[0.7791885,0.2139382,0.004569002,0.00002376911,0.0005758515,0.00005093198,0.00001804331,0.0005450337,0.0006688198,0.00004649645,0.0003630903,0.00001239504],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953609,0.002038918,0.0002237653,0.0002086259,0.0001556048,0.0008842126,0.0003087122,0.00004195286,0.0007773179],"genre_scores_gemma":[0.9938326,0.001910685,0.0006488906,0.0004608974,0.0002697302,0.0009266501,0.0005504898,0.00001153393,0.001388352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003538197,"threshold_uncertainty_score":0.01183641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1143377855832129,"score_gpt":0.4856005969043074,"score_spread":0.3712628113210945,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}